Categories: Business

Finvasia achieves 5 million client base in 190 countries

Fintech firm Finvasia has crossed five million client base in over 190 countries and have transacted trillions of dollar worth in value through its 10-plus brands combined.

Mumbai-headquartered Finvasia, a multinational organisation, owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.

Founded in 2009 by Sarvjeet and Tajinder Virk, Finvasia has blended financial services, healthcare, biomedical engineering, and investment banking.

The company’s first major disruption came in the Indian financial markets with the launch of Shoonya, the country’s first truly zero-commission trading platform. The market responded with millions of traders joining the platform, compelling even the most established brokerage houses to reconsider their pricing structures.

In 2021, Finvasia acquired ZuluTrade, a leading social trading platform that had already facilitated over $2 trillion in trades across over 150 countries.

  • Also read: Retail inflation is expected to settle at 4.1% in Feb’ 25: BoB Economic Research

AI-driven analytics, risk management features and a more collaborative investment environment turned ZuluTrade into a hub where traders, investors and brokers could leverage data-driven insights to make informed decisions.

The company then entered Jumpp, an AI-powered neo-banking super app. Built in collaboration with YES Bank, Jumpp empowers users with real-time spending insights, AI-driven budgeting recommendations, and multilingual support.

Ethniq was one of Finvasia’s pioneering ventures. It developed plant-based, scientifically validated medicines aimed at prevention rather than just treatment. With ten products already approved by FSSAI and AYUSH India, and more awaiting patents.

ActTrader, a professional-grade trading platform, became a cornerstone of Finvasia’s ecosystem, ensuring seamless execution for high-frequency traders and institutional investors.

With Bodyloop, Finvasia ventured into real-time, in-body microsensor technology—an initiative that could redefine how health is monitored. It offers continuous and seamless tracking of vital parameters.

Gini Health is a DNA-based healthcare facility focused on reversing diabetes. Instead of merely managing the disease, Finvasia applied AI-driven diagnostics and genomics to create personalised treatment plans designed to combat diabetes at its root.

Finvasia brokerage and investment banking operations spanned Mauritius, the UAE, South Africa, and the European Union, offering structured finance solutions and strategic advisory services to a diverse clientele.

Source link

nasdaqpicks.com

Recent Posts

Stocks to buy under ₹100: Sumeet Bagadia recommends three shares to buy tomorrow – 10 March 2025

Stocks to buy under ₹100: Indian markets closed Friday’s session on a flat note but…

1 minute ago

Makhana: The superfood revolution in Indian agriculture

Makhana, often hailed as a superfood in the health arena today, has a backstory steeped…

5 minutes ago

KFin Tech stock crashes 50% but retains its premium over CAMS. What’s next?

KFin performed brilliantly during the most recent bull run, gaining 300% between December 2022 and…

13 minutes ago

Expert view: Indian stock market to stay flat to negative for a few months, says Jayesh Faria of Motilal Oswal

Expert view: Jayesh Faria, Director and Regional Head – West at Motilal Oswal Private Wealth,…

25 minutes ago

Bridgestone and Michelin test advances in puncture-free tyres

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…

34 minutes ago

Stocks to buy or sell: Dharmesh Shah of ICICI Securities suggests buying Kotak Bank, Tata Power tomorrow – 10 March 2025

Stock Market news: The major domestic indices, Nifty 50 and Sensex, concluded Friday's trading session…

36 minutes ago